The U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

Existing Users Log In
   
Forgot password? Click here to reset
New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field